Prostate Cancer Treatment Market is Expected to Reach $11.88 bn by 2026

The Prostate Cancer Treatment Market was valued at US$8.26 billion in the year 2018 and is estimated to reach US$11.88 billion by 2026, at a CAGR of 4.65%.

Prostate cancer is a cancer of the prostate gland, 99% is of adenocarcinoma type developing in the gland cells and the rest 1% being sarcoma type arising in the tissues and distinguishable into transitional cell carcinoma, small cell carcinoma, and neuroendocrine tumor. Prostate cancer is the 4th most commonly occurring cancer and the 2nd most common among men with 1.3 million cases detected in 2016. The average age of occurrence is above 60 and rarely occurs below the age of 40. There is no specific causative for prostate cancer nevertheless age, obesity and overweight, ethnicity, family history, smoking, diet, and genetic mutation are attributed to its occurrence.

France, UK, Australia, Switzerland, and Ireland feature in the top 20 list of countries with more incidence. Whilst, US estimates suggest approximately 174600 men will be diagnosed with prostate cancer in 2019. Besides, the consistent increase in the worldwide prostate cancer numbers y-o-y is driving the market growth.

Digital Rectal Examination (DRE), Prostate-Specific Antigen (PSA) test, ultrasound, MRI fusion, and prostate biopsy is prescribed for the diagnosis of prostate cancer. Besides CT Scan, PET scan, the Bone scan is also used to assess the metastasis. Active surveillance, surgery, radiation therapy, chemotherapy, hormone therapy, and immune therapy are the predominant treatments available. Recently, cryotherapy and precision medicine for treating prostate cancer are underway.

This study provides the latest insights on the industry trends, products & pipeline along with country, regional and global revenue forecast till the year 2026. The analysis of the market is segmented into Treatment Outlook (Surgery, Radiation Therapy, Hormone Therapy, Chemotherapy, Immunotherapy, and Targeted therapy) and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Hormonal therapy, specifically androgen deprivation therapy (ADT) reduces male hormone androgen that aid in cancer metastasis. Zytiga from Johnson & Johnson was the first choice for treating prostate cancer. EU patent of Zytiga expires in 2021 and Japan patent expires in 2021. Nevertheless, Zytiga US patent expiring soon, the branded drug sale is expected to slide down as the generics are expected to capture the market. Xtandi from Astellas Pharma already closing into the sales of Zytiga, preferably, Xtandi is expected to take over the market share soon in the hormonal therapy segment. The emergence of immune and targeted therapies used for treating advanced metastatic form are also expected to contribute to the market share. Whereas, generic drug sales are expected to contribute to overall drug sales by more than 20%.

North America region dominates the market share with an increase in prevalence, adoption of new technologies, improved health care infrastructure, awareness, high R&D investments and more therapies in the pipeline waiting to be released during the forecast period is expected to drive the market growth. European region falls next in the line of the contribution to the market with the Asia Pacific region steadily catching up. Government interests in rising awareness on screening and diagnosis of prostate cancer are expected to fuel the market growth.

The major players in the market include Johnson & Johnson, Astellas Pharma, Sanofi-aventis, Ipsen Pharma, Bayer AG, AstraZeneca, Valeant Pharmaceuticals and many more… With more metastatic castration-resistant prostate cancer (mCRPC) based drugs lined in for approval, the new mechanism-based treatment is set to change the course of prostate cancer treatment and the drug sales patterns during the forecast period.

Request for Sample Pages @

Research Scope

  • Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.

  • Provides a Comparative Analysis of Key Marketed and Pipeline Products.

  • Provides Key Information on Players involved.

  • Provides a Complete Overview of Market Segments and the Regional Outlook.

  • Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.

The Report Provides Key Insights on

  • History of the Prostate Cancer Treatment Market, 2015 to 2017

  • Forecast of the Prostate Cancer Treatment Market Growth till the year 2026

  • The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Prostate Cancer Treatment Market

  • Analysis of potential growth segments which will drive the market

  • Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market

  • Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics

Download Complete TOC of the Report @

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.


Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)